News
ANNX
4.010
+10.16%
0.370
Weekly Report: what happened at ANNX last week (0921-0925)?
Weekly Report · 22h ago
Insider Spends US$100k Buying More Shares In Annexon
Simply Wall St · 1d ago
Annexon: Preserving Patient Function Is The Real Investment Opportunity
Seeking Alpha · 1d ago
Weekly Report: what happened at ANNX last week (0914-0918)?
Weekly Report · 09/21 10:16
Analysts Offer Insights on Healthcare Companies: Rocket Doctor AI (OtherAIRDF) and Annexon Biosciences (ANNX)
TipRanks · 09/16 09:01
Weekly Report: what happened at ANNX last week (0907-0911)?
Weekly Report · 09/14 10:21
Weekly Report: what happened at ANNX last week (0831-0904)?
Weekly Report · 09/07 10:14
Annexon Is Maintained at Overweight by JP Morgan
Dow Jones · 09/01 18:44
Annexon Price Target Raised to $14.00/Share From $10.00 by JP Morgan
Dow Jones · 09/01 18:44
JP Morgan Maintains Overweight on Annexon, Raises Price Target to $14
Benzinga · 09/01 18:34
Annexon price target raised to $14 from $10 at JPMorgan
TipRanks · 09/01 12:10
Weekly Report: what happened at ANNX last week (0824-0828)?
Weekly Report · 08/31 10:22
Annexon Biosciences Bets Big on Pivotal Trial Wins
TipRanks · 08/27 00:14
Weekly Report: what happened at ANNX last week (0817-0821)?
Weekly Report · 08/24 10:22
Expanded ARCHER II Trial And New Credit Facility Might Change The Case For Investing In Annexon (ANNX)
Simply Wall St · 08/21 22:28
Annexon participates in a conference call with JPMorgan
TipRanks · 08/17 15:56
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 08/17 15:05
Weekly Report: what happened at ANNX last week (0810-0814)?
Weekly Report · 08/17 10:23
Annexon expands Phase 3 ARCHER II trial
TipRanks · 08/17 10:15
Annexon (ANNX), Why Is The Market Paying Closer Attention?
Simply Wall St · 08/16 15:19
More
Webull provides a variety of real-time ANNX stock news. You can receive the latest news about Annexon, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ANNX
Annexon, Inc. is a biopharmaceutical company advancing targeted immunotherapies aimed at complement-mediated neuroinflammatory diseases. It identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology. Tanruprubart is an investigational-targeted immunotherapy delivered in a single infusion to rapidly halt aggressive neuroinflammation and damage in GBS, an acute, rare, neuromuscular emergency. The Vonaprument is an investigational neuroprotective inhibitor of C1q and the classical complement cascade delivered intravitreally for dry AMD with GA, a leading cause of blindness. ANX1502, a novel oral small molecule for autoimmune conditions. The Company's next wave programs include ANX005 and ANX009. ANX009, a C1q-blocking Fab formulated for subcutaneous delivery, for patients with lupus nephritis.